期刊文献+

肝癌乙型肝炎病毒标志物模式与病毒载量的临床观察 被引量:3

Clinical observation of sign mode and quantity of B type hepatitis of liver cancer
下载PDF
导出
摘要 目的:探讨原发性肝癌的发生与乙型肝炎标志物及乙肝病毒载量的关系。方法:对125例乙型病毒感染的原发性肝癌进行乙肝病毒标志物检测。其中31例检测了乙型肝炎病毒载量。结果:发现肝癌中乙肝病毒标志物HbsA g(+),HbeA b(+),HbcA b(+)模式59例(47.2%),占第一位。HbsA g(+),HbcA b(+)模式37例(29.6%),占第二位,它们分别与HbsA g(+),HbeA b(+),HbcA b(+)模式21例(16.8%)相比,有显著性差异。31例肝癌检测乙肝病毒载量在106cop ies/mL以下。结论:HbsA g(+),HbeA b(+),HbcA b(+)模式和HbsA g(+),HbcA b(+)模式是原发性肝癌的主要模式,原发性肝癌病毒载量不高。 Objective:To investigate the relationships between the sign mode and quantity of B type hepatitis and primary liver cancer.Methods:Sign mode of B type hepatitis were determined on 125 primary liver cancer patients who suffered from B type hepatitis,among which 31 cases received detection of the quantity of B type hepatitis.Results:Fifty-nine cases of HbsAg(+),HbeAb(+) and HbcAb(+) mode of B type hepatitis were found in liver cancer patients(47.2%),and 37 cases of HbsAg(+) and HbcAb(+) mode were the second most one(9.6%),which had significant differences with the mode of HbsAg(+),HbeAb(+) and HbcAb(+)(21 cases,16.8%).The quantity of B type hepatitis of 31 cases of liver cancer patients were below 106 copies/mL.Conclusion:Mode of HbsAg(+),HbeAb(+) and HbcAb(+) and mode of HbsAg(+) and HbcAb(+) were the main ones of primary liver cancer,and the quantity of B type hepatitis was not too much.
出处 《临床医药实践》 2007年第S1期488-490,共3页 Proceeding of Clinical Medicine
关键词 肝癌 乙型肝炎病毒标志物 乙型肝炎病毒载量 liver cancer sign mode of B type hepatitis quantity of B type hepatitis
  • 相关文献

参考文献3

二级参考文献19

  • 1叶本法,沈靖,徐耀初,钮菊英,陈建国,张宝初,柳标,姜允辉.HBV、HCV感染与HCC发生关系的病因学研究[J].中华流行病学杂志,1994,15(3):131-134. 被引量:35
  • 2陈益,汤钊猷,李君,刘康达,邹合强.慢性乙型肝炎病毒感染与肝细胞性肝癌中突变型p53蛋白的表达[J].中华肿瘤杂志,1994,16(3):184-187. 被引量:25
  • 3[1]Merican I, Guan R, Amarapuka D, et al. Chronic hepatitis B virus infection in Asian countries[J]. J Gastroenterol Hepatol, 2000, 15:1356-61.
  • 4[2]Zuckerman AJ. More than third of world's population has been infected with hepatitis B virus[J]. Br Med J, 318:1213.
  • 5[3]Parkin DM, Pisani P, Munoz N, et al. The global health buden of infection associated cancers[J]. Cancer surveys, 1999, 33:5-33.
  • 6[4]Lau GK, Cantan WF, Locamini SA, et al. Treatment of chronic hepatitis B virus infection: An Asia - Pacific perspective[J]. J G, astroenterol &Hepatol, 1999,14:3- 12.
  • 7[5]Chen DS. Public health measures to control hepatitis B virus infection in the developing countries of the Asia - Pacific region[ J ]. J Gastroenterol & Hepatol, 2000, 15(suppl.):E7- 10.
  • 8[6]Liaw YF, Tai DI, Chu CM, et al. The development of cirrhosis in pa- tiests with chronic type B hepatitis: a prospective study[J]. Hepatol,1988, 8:493-496.
  • 9[7]Yun MH, Hsu FC, Sheen IS, et al. Prospective study of hepatocellular carcinoma and cirrhosis in a symptomatic hepatitis B virus carriers[J].Am J Epidemiol, 1997, 145:1039-47.
  • 10[8]Lai CL, Haw YF, Leung N, et al. A 12 month course of lamivudine (100 mg qd) therapy improved liver histology: Results of a placebo controlled multicentre study in Asia[J]. J Hepatol, 1997, 26(suppl. 1) :79.

共引文献24

同被引文献20

引证文献3

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部